GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in ...

GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...

The latest updates in the health sector involve significant trials and approvals. GSK's ovarian cancer drug trial met its ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial.